# A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)

> **NCT04524910** · — · COMPLETED · sponsor: **Bayer** · enrollment: 28 (actual)

## Conditions studied

- Myopic Choroidal Neovascularization

## Interventions

- **DRUG:** Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT04524910
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-16
- **Primary completion:** 2022-10-17
- **Final completion:** 2022-11-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04524910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04524910, "A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04524910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*